Articles From: BioSpecifics Technologies Corp. Announces Online Publication in The Journal of Urology of Results from the IMPRESS Trials of XIAFLEX® in Peyronie's Disease to Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High


2013/3/26
LYNBROOK, N.Y. , March 26, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp.
Sign-up for BioSpecifics Technologies Corp. Announces Positive Top-line Data from XIAFLEX® Phase IIa Study for Frozen Shoulder investment picks
2013/2/27
LYNBROOK, N.Y. , Feb.
Sign-up for BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences investment picks
2013/5/10
LYNBROOK, N.Y. , May 10, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp.
Sign-up for BioSpecifics Technologies Corp. Reports First Quarter 2013 Financial Results investment picks
2013/3/12
LYNBROOK, N.Y. , March 12, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp.
Sign-up for BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results investment picks
2013/5/3
LYNBROOK, N.Y. , May 3, 2013 /PRNewswire/ --   BioSpecifics Technologies Corp.
Sign-up for BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013 investment picks
2013/3/5
LYNBROOK, N.Y. , March 5, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp.
Sign-up for BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013 investment picks
2013/5/28
LYNBROOK, N.Y. , May 28, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp.
Sign-up for BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference investment picks
2013/5/16
XIANYANG, China , May 16, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced financial results of the first quarter ended March 31, 2013 .
Sign-up for Biostar Pharmaceuticals, Inc. Announces First Quarter 2013 Financial Results investment picks
2013/4/15
XIANYANG, China , April 15, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced financial results for the full year ended December 31, 2012 .
Sign-up for Biostar Pharmaceuticals, Inc. Reports 2012 Results investment picks
2013/4/9
XIANYANG, China , April 9, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its 2012 year-end financial results will be released before the market open on Monday, April 15, 2013 .
Sign-up for Biostar Pharmaceuticals, Inc. to Host Fiscal 2012 Year End Earnings Conference Call on Monday, April 15, 2013 at 9:30 a.m. ET investment picks
2013/5/14
XIANYANG, China , May 14, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that management will hold a conference call to discuss its 2013 first quarter performance at 9:00 a.m. ET on Thursday, May 16, 2013 .
Sign-up for Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2013 First Quarter Earnings Conference Call on Thursday, May 16, 2013 at 9:00 a.m. ET investment picks
2013/6/11
ATLANTA, June 11, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that it has commenced dosing in a multi-national, randomized, double blind, placebo controlled, parallel arm Phase 2 clinical trial of laninamivir octanoate, a long-acting neuraminidase inhibitor.
Sign-up for Biota Initiates Phase 2 Trial of Laninamivir Octanoate for the Treatment of Influenza in Adults investment picks
2013/5/6
ATLANTA, May 6, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignations of Dr.
Sign-up for Biota Pharmaceuticals Announces Changes to Its Board of Directors investment picks
2013/4/15
ATLANTA, April 15, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that its Board of Directors has adopted a revised corporate strategy following the recent completion of management's strategic and operational review of the organization and its various development programs.
Sign-up for Biota Pharmaceuticals Announces Results of Strategic and Operational Review investment picks
2013/5/10
ATLANTA, May 10, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month period ended March 31, 2013, and provided an update on recent corporate developments.
Sign-up for Biota Pharmaceuticals Reports Second Quarter Financial Results and Corporate Update investment picks
2013/2/1
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=980933&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Companies Attractive Targets for Pharma Companies Looking to Replace Lost Revenues investment picks
2013/1/30
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=979805&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Companies Attractive Targets for Pharma Companies Looking to Replace Lost Revenues investment picks
2013/1/31
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=980427&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues investment picks
2013/2/8
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=983555&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues investment picks
2013/2/6
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=982547&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues investment picks
2013/1/30
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=979811&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Expected to Experience More Merger & Acquisition Activity in 2013 investment picks
2013/3/8
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=994560&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Looks to Benefit From FDA's New "Breakthrough" Designation investment picks
2013/3/8
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=994571&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High investment picks
2013/3/7
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=994131&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High investment picks
2013/3/6
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=993612&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High investment picks
2013/3/4
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=992453&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High investment picks
2013/3/1
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=991871&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High investment picks
2013/2/19
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=987114&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High investment picks
2013/2/27
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=990746&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: BioSpecifics Technologies Corp. Announces Online Publication in The Journal of Urology of Results from the IMPRESS Trials of XIAFLEX® in Peyronie's Disease to Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity